Goldman Sachs Portfolio holdings
Goldman Sachs, founded in 1869 by Marcus Goldman and later joined by Samuel Sachs, is a premier global investment bank headquartered in New York City, renowned for its influential role in financial markets. The firm provides a wide range of services, including investment banking (mergers, acquisitions, and underwriting), securities trading, asset management, and consumer banking through its Marcus platform, catering to corporations, governments, institutions, and high-net-worth individuals. Known for its elite status on Wall Street, Goldman Sachs has a history of navigating major economic events, from the Great Depression to the 2008 financial crisis, where it played a controversial yet pivotal role. With a strong emphasis on innovation and a global footprint, it manages billions in assets and remains a powerhouse in shaping economic policy and market trends.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Total Bond Market
BND
|
+$1.02B |
| 2 |
Canadian Natural Resources
CNQ
|
+$958M |
| 3 |
iShares Core US Aggregate Bond ETF
AGG
|
+$896M |
| 4 |
Vanguard S&P 500 ETF
VOO
|
+$861M |
| 5 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$756M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$5.62B |
| 2 |
Amgen
AMGN
|
+$1.68B |
| 3 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$1.18B |
| 4 |
Visa
V
|
+$1.05B |
| 5 |
Invesco QQQ Trust
QQQ
|
+$1B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.79% |
| 2 | Healthcare | 9.32% |
| 3 | Financials | 8.97% |
| 4 | Consumer Discretionary | 7.33% |
| 5 | Industrials | 5.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1926
Alignment Healthcare
ALHC
$2.78B
| $20.4M | 0.01% |
1,733,316
-438,500
| -20% | -$5.33M |
|
1927
Aegon
AEG
$14B
| $20.4M | 0.01% |
4,042,557
-39,845
| -1% | -$185K |
|
1928
PTC Therapeutics
PTCT
$5.91B
| $20.3M | 0.01% |
533,034
+27,556
| +5% | +$1.15M |
|
1929
Hanmi Financial
HAFC
$954M
| $20.3M | 0.01% |
821,238
+9,413
| +1% | +$240K |
|
1930
GATX Corp
GATX
$6.31B
| $20.3M | 0.01% |
190,684
+17,622
| +10% | +$1.83M |
|
1931
Papa John's
PZZA
$811M
| $20.3M | 0.01% |
246,162
+24,223
| +11% | +$1.9M |
|
1932
Calix
CALX
$2.36B
| $20.3M | 0.01% |
296,058
+49,301
| +20% | +$3.31M |
|
1933
CRISPR Therapeutics
CRSP
$4.99B
| $20.2M | 0.01% |
497,233
-248,673
| -33% | -$13.2M |
|
1934
iShares 3-7 Year Treasury Bond ETF
IEI
$17.7B
| $20.2M | 0.01% |
175,910
+172,550
| +5,135% | +$19.8M |
|
1935
StoneCo
STNE
$2.69B
| $20.2M | 0.01% |
2,140,627
+117,649
| +6% | +$1.23M |
|
1936
Myriad Genetics
MYGN
$304M
| $20.2M | 0.01% |
1,391,816
-230,505
| -14% | -$4.29M |
|
|
EOCW.U
1937
DELISTED
Elliott Opportunity II Corp. Units, each consisting of one Class A ordinary share and one-fourth of one redeemable warrant
EOCW.U
| $20.2M | ﹤0.01% |
2,000,000
| – | – |
|
1938
PUT
MongoDB
MDB
$29.8B
| $20.2M | ﹤0.01% |
102,500
| – | – |
|
1939
Axalta
AXTA
$8.03B
| $20.1M | ﹤0.01% |
791,087
+9,037
| +1% | +$223K |
|
1940
Rocket Pharmaceuticals
RCKT
$387M
| $20.1M | ﹤0.01% |
1,029,164
-1,007,480
| -49% | -$18.6M |
|
1941
TD Synnex
SNX
$20.7B
| $20.1M | ﹤0.01% |
212,553
+19,345
| +10% | +$1.81M |
|
1942
State Street SPDR Portfolio S&P 500 Value ETF
SPYV
$36.6B
| $20.1M | ﹤0.01% |
516,855
-168,194
| -25% | -$6.44M |
|
1943
Shutterstock
SSTK
$217M
| $20.1M | ﹤0.01% |
381,079
-107,941
| -22% | -$5.5M |
|
1944
Evolent Health
EVH
$404M
| $20.1M | ﹤0.01% |
714,419
-224,468
| -24% | -$6.43M |
|
1945
State Street SPDR Portfolio S&P 500 High Dividend ETF
SPYD
$8.71B
| $20.1M | ﹤0.01% |
506,705
+64,997
| +15% | +$2.54M |
|
1946
Celldex Therapeutics
CLDX
$3.26B
| $20M | ﹤0.01% |
449,584
-214,847
| -32% | -$7.67M |
|
1947
Applied Industrial Technologies
AIT
$13.3B
| $20M | ﹤0.01% |
158,882
-28,944
| -15% | -$3.55M |
|
1948
NovoCure
NVCR
$1.83B
| $20M | ﹤0.01% |
272,633
+3,036
| +1% | +$228K |
|
1949
CALL
State Street SPDR S&P Oil & Gas Exploration & Production ETF
XOP
$3.52B
| $20M | ﹤0.01% |
146,900
-43,100
| -23% | -$6.25M |
|
1950
PUT
Las Vegas Sands
LVS
$29.9B
| $20M | ﹤0.01% |
415,200
+164,300
| +65% | +$6.97M |
|
Similar funds
Goldman Sachs's Q4 2022 Portfolio in Review
As of Q4 2022, Goldman Sachs held 6,669 positions worth $408B, up 3.1% from $396B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Goldman Sachs withdrew a net $13.2B in Q4 2022, closing 721 positions and reducing 2,588 holdings. Its most notable exit was ChemoCentryx, Inc., an estimated $290M position sold in full.
By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 15% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Goldman Sachs opened a new position in Perfect Corp worth $104M.
- Goldman Sachs's largest Q4 2022 buy was Perfect Corp: 14,518,235 shares worth $104M.
- Goldman Sachs added most to Vanguard Total Bond Market in Q4 2022, an estimated $1.02B increase.
- Goldman Sachs's biggest Q4 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $5.62B.
- Goldman Sachs fully exited ChemoCentryx, Inc. in Q4 2022, selling an estimated $290M.
- Goldman Sachs's ten largest holdings make up 15% of its $408B portfolio in Q4 2022.
- Goldman Sachs opened 429 new positions and closed 721 in Q4 2022.
- Goldman Sachs's portfolio value rose 3.1% quarter-over-quarter to $408B.
Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.